EGFR and neoplasm: Furthermore, afatinib, a second‐generation EGFR‐TKI, potently inhibits p.L747P mutant cells, reduces EGFR phosphorylation and downstream signaling, and significantly suppresses p.L747P mutant tumor growth.11